Antiestrogen resistance in ER positive breast cancer cells
- PMID: 7881107
- DOI: 10.1007/BF00666162
Antiestrogen resistance in ER positive breast cancer cells
Abstract
Acquisition of the antiestrogen resistance by breast cancer cells in vivo may result from a variety of mechanisms. The main pathway appears to involve loss of estrogen receptor (ER) expression or selection for ER negative cells among heterogenous population of tumor cells. However, clinical data suggest that, in about 30% of the cases, antiestrogen resistance arises even in the presence of estrogen receptors. Postulated mechanisms leading to the latter phenotype include selection for variant receptor forms during treatment, development of novel metabolic pathways for the drug, loss of nuclear co-factors, or activation of signal transduction pathway that cross activate ER signals. We have used an in vitro experimental system utilizing LY-2 cell line, an ER positive and antiestrogen resistant MCF-7 cell variant, to study the mechanism of antiestrogen resistance in the presence of functional ER. Result from a complementation experiment suggests that LY-2 phenotype is a recessive trait. Cloning of the genetic defect in the LY-2 cells would provide further insight for the mechanism of antiestrogen resistance in ER positive breast cancer cells.
Similar articles
-
An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.Mol Cell Endocrinol. 1992 Dec;90(1):77-86. doi: 10.1016/0303-7207(92)90104-e. Mol Cell Endocrinol. 1992. PMID: 1301400
-
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.Cancer Res. 1996 May 15;56(10):2321-30. Cancer Res. 1996. PMID: 8625307
-
Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.J Steroid Biochem Mol Biol. 1996 Oct;59(2):121-34. doi: 10.1016/s0960-0760(96)00114-8. J Steroid Biochem Mol Biol. 1996. PMID: 9010327
-
Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.Acta Oncol. 1996;35 Suppl 5:9-14. doi: 10.3109/02841869609083961. Acta Oncol. 1996. PMID: 9142958 Review.
-
[Mechanism of acquired antiestrogen resistance and its management in breast cancer].Nihon Rinsho. 1997 May;55(5):1149-54. Nihon Rinsho. 1997. PMID: 9155167 Review. Japanese.
Cited by
-
Reciprocal regulation of extracellular matrix proteins and ovarian steroid activity in the mammary gland.Breast Cancer Res. 2001;3(6):365-72. doi: 10.1186/bcr324. Epub 2001 Aug 2. Breast Cancer Res. 2001. PMID: 11737887 Free PMC article. Review.
-
Oestrogen receptor: a stable phenotype in breast cancer.Br J Cancer. 1996 Jan;73(1):5-12. doi: 10.1038/bjc.1996.2. Br J Cancer. 1996. PMID: 8554983 Free PMC article. Review.
-
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.J Cancer. 2016 Jun 23;7(10):1281-94. doi: 10.7150/jca.13141. eCollection 2016. J Cancer. 2016. PMID: 27390604 Free PMC article. Review.
-
Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line.Br J Cancer. 1997;75(1):17-27. doi: 10.1038/bjc.1997.4. Br J Cancer. 1997. PMID: 9000593 Free PMC article.
-
Tamoxifen resistance in breast cancer: elucidating mechanisms.Drugs. 2001;61(12):1721-33. doi: 10.2165/00003495-200161120-00004. Drugs. 2001. PMID: 11693462 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical